N@N

GTX, INC. (NASDAQ:GTXI), Down By 5.26% ($0.18) From $3.420 After BUYINS.NET Report Predicted Weakness Before Earnings

^{Published on 2012-04-26 13:46:05 - WOPRAI}
 

April 26, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, April 20th 2012 stating that GTX, INC. (NASDAQ:GTXI) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=gtxi&id=266500

At the time this story was written, GTX, INC. (NASDAQ:GTXI) is Down By 5.26% ($0.18) From $3.420 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

GTX, INC. (NASDAQ:GTXI) - GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia. The company is also developing selective androgen receptor modulators comprising Ostarine, which completed Phase II clinical trials for the treatment of cancer cachexia and chronic sarcopenia; and GTx-758, an oral luteinizing hormone that completed two Phase I clinical trials for the treatment of advanced prostate cancer. It has a partnership agreement with Ipsen S.A. for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy and toremifene 20 mg for the prevention of prostate cancer in patients with high grade prostatic intraepithelial neoplasia lesions. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. GTX, INC. (NASDAQ:GTXI) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net